Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$26199 of $63500 - as of 2024-06-30
41%
Header Image
Reboxitin for ADHD

Sitemap

Reboxitin for ADHD

Reboxitine is a noradrenaline reuptake inhibitor, as well as a weak serotonin reuptake inhibitor.

Trade names: Edronax (D, CH, A), Solcenx (D)

The active ingredient reboxitine is a noradrenergic drug which, according to individual reports, can be effective for ADHD. As an antidepressant, as it was actually intended to be, it was probably quite unsuccessful.

The updated European consensus on the diagnosis and treatment of ADHD (2018) names reboxitine as a possible alternative to atomoxetine for ADHD.1

There is evidence that reboxitine is effective for ADHD. However, there are only a few controlled studies and reboxitine could be used primarily in adults without comorbidities.23

In Germany, Reboxitin is not reimbursed by health insurance companies.